肝切除术后继续服用阿司匹林与出血相关并发症
这项多中心前瞻性观察研究通过倾向性评分匹配比较了择期肝切除患者继续服用阿司匹林与对照组的结局。匹配后每组108例,两组严重出血、术中输血、总体出血、CCI评分、主要并发症及90天死亡率均无统计学显著差异。结论提示继续服用阿司匹林与出血相关并发症增加无关。
要点
- 择期肝切除继续服用阿司匹林未显著增加严重出血风险。
- 匹配后两组术中输血率、总体出血率及90天死亡率相近。
- 主要并发症和CCI评分在两组间无统计学显著差异。
核心结论
- 继续服用阿司匹林与择期肝切除术后出血相关并发症发生率升高无关。
研究设计与样本
- 多中心前瞻性观察研究,比较继续服用阿司匹林组与对照组,并采用倾向性评分匹配分析。
- 匹配前阿司匹林组118例,对照组1685例;匹配后每组各108例。
临床怎么用
- 对于需要继续服用阿司匹林的择期肝切除患者,现有观察性证据不支持因担心出血而常规停药。
局限性
- 研究为观察性设计,可能存在残余混杂。
- 匹配后样本量有限,部分结局置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The operative risk of hepatectomy under antiplatelet therapy is unknown. This study sought to assess the outcomes of elective hepatectomy performed with or without aspirin continuation in a well balanced matched cohort. METHODS: Data were retrieved from a multicentre prospective observational study. Aspirin and control groups were compared by non-standardized methods and by propensity score (PS) matching analysis. The main outcome was severe (Dindo-Clavien grade IIIa or more) haemorrhage. Other outcomes analysed were intraoperative transfusion, overall haemorrhage, major morbidity, comprehensive complication index (CCI) score, thromboembolic complications, ischaemic complications and mortality. RESULTS: Before matching, there were 118 patients in the aspirin group and 1685 in the control group. ASA fitness grade, cardiovascular disease, previous history of angina pectoris, angioplasty, diabetes, use of vitamin K antagonists, cirrhosis and type of hepatectomy were significantly different between the groups. After PS matching, 108 patients were included in each group. There were no statistically significant differences between the aspirin and control groups in severe haemorrhage (6·5 versus 5·6 per cent respectively; odds ratio (OR) 1·18, 95 per cent c.i. 0·38 to 3·62), intraoperative transfusion (23·4 versus 23·7 per cent; OR 0·98, 0·51 to 1·87), overall haemorrhage (10·2 versus 12·0 per cent; OR 0·83, 0·35 to 1·94), CCI score (24 versus 28; P = 0·520), major complications (23·1 versus 13·9 per cent; OR 1·82, 0·92 to 3·79) and 90-day mortality (5·6 versus 4·6 per cent; OR 1·21, 0·36 to 4·09). CONCLUSION: This observational study suggested that aspirin continuation is not associated with a higher rate of bleeding-related complications after elective hepatic surgery.
引用
- Gelli M, Allard MA, Farges O, et al. Use of aspirin and bleeding-related complications after hepatic resection. Br J Surg. 2018. PMID: 29412449. doi:10.1002/bjs.10697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。